Newsroom | IDEAYA Biosciences

Month Year

News Alerts

Jul 11, 2019

IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces initiation of its Phase 1/2...
Jul 9, 2019

IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A, as Vice President, Development Operations

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the promotions...
May 28, 2019

IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $10.00 per share. The gross...
May 22, 2019

IDEAYA Announces Pricing of Initial Public Offering

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before...
May 8, 2019

IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the U.S. Food and Drug...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa

News Releases